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Objective: To investigate the correlation of two important inﬂammatory biomarkers, plasma osteopontin
and neutrophil gelatinase-associated lipocalin (NGAL), with the severity and outcome of pelvic inﬂam-
matory disease (PID).
Materials and methods: Sixty-one patients with PID, including 25 patients with tubo-ovarian abscess
(TOA), were consecutively recruited. Their blood samples were tested for the concentrations of plasma
osteopontin and NGAL using enzyme-linked immunosorbent assay. The associations of these biomarkers
with TOA, length of hospitalization, and incidence of surgery were also analyzed.
Results: Plasma osteopontin level was signiﬁcantly increased in PID patients with TOA compared to PID
patients without TOA (median 107.77 ng/mL vs. 72.39 ng/mL, p ¼ 0.004). However, there was no sig-
niﬁcant difference for plasma NGAL. If the cutoff level of plasma osteopontin was set at 81.1 ng/mL, there
was a 76.0% sensitivity and a 24.0% false negative rate in predicting TOA in PID patients. Plasma osteo-
pontin signiﬁcantly correlated with length of hospital stay (r ¼ 0.467, p < 0.001), and this correlation was
better than that of NGAL. However, neither biomarker was associated with incidence of surgery.
Conclusion: Plasma osteopontin has a better correlation with TOA and length of hospitalization
compared to NGAL. If plasma osteopontin level falls below 81.1 ng/mL, PID patients will have about a 20%
chance of developing TOA. Incorporating plasma osteopontin, but not NGAL, will allow for an adjuvant
diagnostic biomarker for TOA and predictor of length of hospital stay.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Osteopontin, a phosphorylated acidic glycoprotein ﬁrst identi-
ﬁed in bone, is involved in bonemorphogenesis [1]. It is secreted byd School of Medicine, Chung
North Road, Taichung 40201,
om.tw, jlko@csmu.edu.tw
78@csh.org.tw (L.-Y. Lin),
bstetrics & Gynecology. Publishedosteoclasts, osteoblasts, and kidney and endothelial cells, and by
activated immune cells, such as T cells and macrophages [2,3]. It
may regulate inﬂammatory cell mobilization and is strikingly
upregulated at sites of inﬂammation and tissue remodeling, acting
as a pro- and anti-inﬂammatory cytokine [4e6]. Neutrophil
gelatinase-associated lipocalin (NGAL or lipocalin 2) was ﬁrst iso-
lated from speciﬁc granules of human polymorphonuclear neu-
trophils [7]. It is a 25-kDa secretory glycoprotein and belongs to a
large family of lipocalins that comprise a group of more than 20
small secreted proteins deﬁned on the basis of their three-by Elsevier Taiwan LLC. All rights reserved.
Table 1
Basic characteristics and levels of plasma osteopontin and neutrophil gelatinase-
associated lipocalin (NGAL) in patients with pelvic inﬂammatory disease (PID) or
tubo-ovarian abscess (TOA).a
Variables Patients with PID
(n ¼ 36)
Patients with TOA
(n ¼ 25)
p
Osteopontin (ng/mL) 72.39 (43.19e362.59) 107.77 (43.75e415.52) 0.004b
NGAL (ng/mL) 16.83 (7.61e161.39) 22.78 (6.49e386.74) 0.681
Age (y), mean ± SD 34.1 ± 13.1 37.2 ± 11.6 0.353
Socioeconomic status Middle Middle
Resident area Mid-Taiwan Mid-Taiwan
Ethnicity Taiwanese Taiwanese
Regular cigarette
smoking
None None
Regular alcohol
drinking
None None
a Statistical analysis: ManneWhitney U test. A p value <0.05 was considered
signiﬁcant.
b p < 0.05.
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NGAL in bacterial infection before NGAL limits bacterial growth by
sequestering the iron-laden siderophore [9].
Pelvic inﬂammatory disease (PID) is an infection of the female
reproductive system that subsequently induces neutrophil and
macrophage activation to ﬁght against pathogens [10,11]. It is
composed of a spectrum of inﬂammatory disorders of the upper
female genital tract involving the uterus, fallopian tubes, and
ovaries, and can result in an ectopic pregnancy and chronic pelvic
pain. Furthermore, scarring and adhesion formation that accom-
panies healing of damaged oviducts may lead to female infertility of
tubal factor. Because of its wide variation in the symptoms and
signs, ranging from subtle or mild symptom to severe abdominal
pain with abscess, PID is difﬁcult to diagnose and may require
admission and even surgery. Women with tubal factor infertility
apparently induced by past episodes of PID often give no history of
PID [12]. Early diagnosis and treatment may prevent the progres-
sion of PID to the more severe forms, such as tubo-ovarian abscess
(TOA), and decrease the incidence of tubal factor infertility.
To date, there has been no report comparing plasma osteopontin
and NGAL expressions between PID patients and TOA patients. No
studies have investigated their implication in the clinical outcome
of PID. This study hypothesizes that the levels of plasma osteo-
pontin and NGAL are correlated with the severity of PID. Thus, the
purposes of this study are to compare the plasma levels of NGAL
and osteopontin between patients with PID and those with TOA,
and to investigate the correlation of these biomarkers with the
clinical outcomes of PID patients in terms of need for surgery and
length of hospital stay.
Materials and methods
Participants and sample collection
This hospital-based study consecutively recruited 61 PID pa-
tients who received treatment at the Department of Obstetrics and
Gynecology of Chung Shan Medical University Hospital, Taichung,
Taiwan between April 2006 and September 2007. Among them, 25
were diagnosed as having TOA. Diagnosis of PID was based on the
characteristic criteria set by the Centers for Disease Control and
Prevention (CDC) for PID. Patients with pelvic or lower abdominal
pain of no known origin and either uterine/adnexal tenderness or
cervical motion tenderness were diagnosed as PID. By contrast, TOA
was deﬁned by the presence of a palpable adnexal mass and abscess
in a tubo-ovarian mass on pelvic sonography in PID patients.
All PID patients were admitted to the wards of the Gynecology
Department from the emergency room, where computed tomog-
raphy scanning was done to rule out appendicitis and pelvic tumors
other than TOA. Women who were pregnant, breastfeeding, taking
antibiotics, suffering from major comorbidities such as heart dis-
ease and hypertension, suspected of having tumors originating
from any organ except TOA, or had undergone gynecologic surgery
within 3 weeks prior to admission, were excluded from the study.
All PID patients in the wards received treatment based on the
protocols suggested by the CDC. They received the same regimens
of antibiotics, which were given intravenously for at least 3 days, or
for an additional 24 hours after they were afebrile. Oral antibiotics
were given thereafter until Day 14 of treatment.
If clinical signs or symptoms such as pelvic pain or fever did not
improve or became exacerbated, if signs of TOA rupture or misdi-
agnosis of adnexal malignant tumor were suspected, or if medical
treatment failed, surgery was performed to conﬁrm the diagnosis
and as deﬁnitive treatment.
The mean age and SD of patients with PID and TOA were
34.1 ± 13.1 years and 37.2 ± 11.6 years (p ¼ 0.353), respectively.Sixty-one blood samples were collected prior to treatment and
were analyzed for plasma concentrations of osteopontin and NGAL.
The results were then compared between PID patients and TOA
patients. The parameters were measured by clinical laboratory staff
members who were blinded to the study. The hospital's Institu-
tional Review Board approved the study and all of the participants
provided written informed consent.Measurements of plasma osteopontin and NGAL
Plasma osteopontin and NGAL levels were analyzedwith human
osteopontin enzyme-linked immunosorbent assay (ELISA) kits
(R&D Systems, Abingdon, UK) and human NGAL ELISA kits (R&D
Systems), respectively. From each plasma sample, 50e100 mL was
directly transferred to the microtest strip wells of the ELISA plate
and then assayed according to the manufacturer's instructions.
Absorbance was measured at 450 nm in a microtest plate spec-
trophotometer, and osteopontin and NGAL levels were separately
quantiﬁed with a calibration curve using human osteopontin and
NGAL as standards, respectively.Statistical analysis
The ManneWhitney U test was used to test the statistical sig-
niﬁcance of differences in plasma levels of osteopontin and NGAL
between 36 PID patients and 25 TOA patients before they received
treatment. The biomarkers were also compared between PID pa-
tients who received surgery and those who did not. Spearman's
rank correlation analysis was used to correlate these biomarkers
with length of hospital stay.Results
Among the 61 PID patients, 25 patients had TOA. No sepsis or
organ failure cases were found in these patients. The basic char-
acteristics of patients with PID or TOA are shown in Table 1. The
level of plasma osteopontin was signiﬁcantly increased in PID pa-
tients with TOA compared to PID patients without TOA (median
107.77 ng/mL vs. 72.39 ng/mL, p ¼ 0.004; Table 1). However, there
was no signiﬁcant difference for plasma NGAL (median 22.78 ng/
mL vs. 16.83 ng/mL, p ¼ 0.681; Table 1). If 81.1 ng/mL was set as a
cutoff level of plasma osteopontin for differentiating TOA patients
from other PID patients, sensitivity and the speciﬁcity would be
76.0% and 63.9%, respectively, using a receiver operating charac-
teristic curve (Table 2).
Table 2
The sensitivity, speciﬁcity, positive and negative predictive values (PPV and NPV),
accuracy, and likelihood ratios of positive and negative results (LR＋ and LR) of
plasma osteopontin in discriminating between tubo-ovarian abscess (TOA) and
pelvic inﬂammatory disease (PID).a,b
Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
Accuracy
(%)
LR＋ LR
Plasma
osteopontin
76.0 63.9 59.4 79.3 68.9 2.11 0.38
a Sensitivity ¼ the number of patients with TOA with positive results/the number
of patients with TOA; speciﬁcity¼ the number of PID women without TOA and with
negative results/the number of PID women without TOA; PPV ¼ the number of
women with positive results and TOA/the number of PID patients with and without
TOA, but with positive results; NPV ¼ the number of women with negative results,
with PID but without TOA/the number of PID patients with and without TOA, and
who had negative results; accuracy ¼ the number of PID patients with TOA and
positive results plus the number of PID women without TOA and who had negative
results/number of all TOA patients plus all PID women without TOA; LR＋ ¼ the
probability of positive results for patients with TOA/the probability of positive re-
sults for PID women without TOA; LR ¼ the probability of negative results for
patients with TOA/the probability of negative results for PID women without TOA.
b The cutoff level of plasma osteopontin for TOA was 81.1 ng/mL based on 25 PID
patients with TOA and 36 PID patients without TOA using the receiver operating
characteristic curve. When the plasma osteopontin concentration was higher than
the cutoff level, this was regarded as a positive result.
Fig. 1. (A) Plasma osteopontin exhibits a better correlation with the length of hospital
stay (Spearman correlation coefﬁcient r ¼ 0.467, p < 0.001) compared to (B) NGAL
(Spearman correlation coefﬁcient r ¼ 0.272, p ¼ 0.034).
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50 patients received medical treatment. Considering the correla-
tion of plasma osteopontin with need for surgery, there was no
signiﬁcant difference between the 11 PID patients who received
surgery and the 50 medically treated PID patients (median
90.14 ng/mL vs. 82.86 ng/mL, p ¼ 0.442; Table 3). There was also no
signiﬁcant difference for plasma NGAL between PID patients who
received surgery and the medically treated patients (median
26.20 ng/mL vs. 16.44 ng/mL, p ¼ 0.348; Table 3).
Both biomarkers were correlated with the length of hospitali-
zation. Plasma osteopontin had a better correlationwith the length
of hospital stay (Spearman's correlation coefﬁcient r ¼ 0.467,
p < 0.001; Fig. 1A) compared to NGAL (Spearman's correlation co-
efﬁcient r¼ 0.272, p¼ 0.034; Fig.1B). However, plasma osteopontin
level did not show signiﬁcant correlation with that of NGAL
(Spearman's correlation coefﬁcient r ¼ 0.07, p ¼ 0.591).Discussion
Previous studies have found that the level of plasma osteopontin
is elevated in patients with PID compared to that of healthywomen,
and decreased signiﬁcantly after treatment [13]. Plasma NGAL level
also signiﬁcantly increases in patients with PID before they
received treatment compared to that of control individuals [14],
and also decreases after treatment. As such, both plasma osteo-
pontin and NGAL may act as diagnostic adjuvant biomarkers forTable 3
Levels of plasma osteopontin and neutrophil gelatinase-associated lipocalin (NGAL)
in pelvic inﬂammatory disease (PID) patients who received medical treatment or
surgery.a
Patients with PID (n ¼ 50)
who received medical
treatment
Patients with PID
(n ¼ 11) who
received surgery
p
Median (range) Median (range)
Osteopontin
(ng/mL)
82.86 (43.19e362.59) 90.14 (48.81e415.52) 0.442
NGAL (ng/mL) 16.44 (6.49e386.74) 26.20 (7.61e385.06) 0.348
a Statistical analysis: ManneWhitney U test. A p value <0.05 was considered
signiﬁcant.PID. However, their application in the severity and clinical outcome
of PID is still unclear and needs to be deﬁned.
To date, this study is the ﬁrst one to investigate the correlation of
plasma osteopontin and NGALwith other signs of PID severity, such
as TOA, and clinical outcome. In TOA, the more severe form of PID,
patients had higher plasma osteopontin concentrations than those
without TOA. However, this ﬁnding was not demonstrated in
plasma NGAL. This may be because osteopontin can modify chronic
inﬂammatory responses, which is characterized by the persistence
of macrophages at sites of injury and disease [15,16]. It is particu-
larly important in promoting the migration and retention of mac-
rophages at sites of acute and chronic inﬂammation.
The present investigation puts emphasis on the association
between plasma osteopontin and prolonged inﬂammation of PID
such as TOA. Diao et al [17] had similar ﬁndings, in that the level of
plasma osteopontin in severe Streptococcus pyogenes infection was
higher than during a common infection in mice. Its level correlated
with the severity of the S. pyogenes infection. By contrast, NGAL is
regarded as an acute phase protein and its expression is upregu-
lated under different inﬂammatory conditions [18]. Shapiro et al
[19] found that increased plasma NGAL in patients with suspected
sepsis at the emergency department was associated with the
development of acute kidney injury. Their ﬁndings support NGAL as
a promising biomarker for acute kidney injury.
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sensitivity rate is 76.0% and the false negative rate is 24% in pre-
dicting TOA in PID patients, based on the receiver operating char-
acteristic curve. Hence, the negative predictive value is 79.3%. This
implies that once the level of plasma osteopontin falls below
81.1 ng/mL, PID patients will only have about 20% chance of
developing TOA. Because the clinical manifestations of TOA are
sometimes obscure and physical examination is not sensitive
enough, incorporating plasma osteopontin level will be helpful in
the diagnosis of PID patients with TOA as it may act as an adjuvant
diagnostic biomarker for TOA.
Furthermore, plasma osteopontin exhibits a signiﬁcant corre-
lation with the length of hospital stay. The correlation of plasma
osteopontinwith length of hospitalization is also better than that of
NGAL, implying that PID patients with higher plasma osteopontin
concentrations need longer time for treatment in a hospital setting.
To date, few studies have correlated the level of plasma osteopontin
with severity of PID, especially for its application in the prediction
of length of hospital stay. Although the level of plasma osteopontin
may distinguish TOA patients from PID patients, there is no doubt
that TOA is a subtype of PID, which means that when the diagnosis
of PID is established and a cystic complex lesion is found simulta-
neously by ultrasound, the diagnosis of TOA is made.
Aside from age, there are no signiﬁcant differences in terms of
socioeconomic status, residence area, ethnicity, cigarette smoking
status, and alcohol drinking status in all of the PID patients. They all
received the same treatment protocols as suggested by the CDC,
including antibiotic regimens and criteria for surgery, so that the
confounding factors to diagnose TOA or hospitalize may be
decreased in this study. Therefore, the conditions applied may
point to an informative diagnostic adjuvant for predicting the
length of hospitalization, which in this study is the plasma osteo-
pontin level.
Although both plasma osteopontin and NGAL levels are not
associated with the need for surgery in patients with PID, this may
indicate that PID patients with higher plasma osteopontin have
poor clinical courses irrespective of medical treatment or surgery.
This also suggests a more aggressive treatment for PID patients
with higher plasma osteopontin levels.
Interestingly, MMP-9 was included for correlation with PID
severity, such as TOA, length of hospital stay, and incidence of
surgery for the same patients. However, there was no signiﬁcant
relationship among MMP-9 and TOA (p ¼ 0.235, data not shown)
and incidence of surgery (p ¼ 0.548). The plasma level of MMP-9
also did not show a signiﬁcant correlation with the length of hos-
pital stay (Spearman's correlation coefﬁcient r ¼ 0.176, p ¼ 0.175).
When the concentrations of osteopontin, NGAL, MMP-9, C-reactive
protein, and WBC and neutrophil counts were included into
multivariate analysis for distinguishing TOA from PID, plasma
osteopontin level, but not NGAL or MMP-9, exhibited a statistical
associationwith TOA (p¼ 0.044, data not shown). Although plasma
levels of MMP-9 or NGAL may be used to distinguish patients with
PID from normal controls as in a previous investigation [14,20],
some biomarkers may only be suitable to differentiate patients
with PID from healthy women but not to correlate them with PID
severity.
This study has several limitations. There are no cases of sepsis,
organ failure, and other signs of infections such that data of in-
fectious bacteria are not fully available in this study. In addition, the
sample size may not be large enough. As a result, a more detailed
analysis, including sepsis presence, organ failure, or infectious or-
ganisms, could not be performed. If the data were collected more
completely, the potential of plasma osteopontin or NGAL as
markers of severity and outcome prediction would be even more
informative.In conclusion, plasmin osteopontin level does not show a sig-
niﬁcant difference between surgically treated and medically
treated PID patients but is signiﬁcantly correlated with TOA and
length of hospital stay. The incorporation of plasma osteopontin,
but not NGAL, as an adjuvant diagnostic biomarker for TOA and a
predictor of length of hospitalization allows for better decision-
making as regards active or aggressive management of patients
with PID.
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